Cargando…

Raltegravir use in special populations

Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naïve and triple class resistant patients. It also has an excellent tolerability profile and lacks significant drug-drug interactions making i...

Descripción completa

Detalles Bibliográficos
Autor principal: Johnson, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516827/
https://www.ncbi.nlm.nih.gov/pubmed/19959416
http://dx.doi.org/10.1186/2047-783X-14-S3-43
_version_ 1782252348627746816
author Johnson, Margaret
author_facet Johnson, Margaret
author_sort Johnson, Margaret
collection PubMed
description Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naïve and triple class resistant patients. It also has an excellent tolerability profile and lacks significant drug-drug interactions making it an important drug in the treatment of a number of special patient populations. In this review its use in patients undergoing solid organ and bone marrow transplantation and patients receiving cancer chemotherapy, will be discussed. In addition other indications including patients with metabolic complications of existing antiretroviral drugs as well as patients with side effects on current HAART regimens. Other groups of patients where raltegravir may play an important role are patients with renal disease and tuberculosis. Finally, although not licensed for use in pregnancy, raltegravir may need to be considered in some pregnant women with antiretroviral resistance or tolerability issues with current HAART regimens.
format Online
Article
Text
id pubmed-3516827
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35168272012-12-11 Raltegravir use in special populations Johnson, Margaret Eur J Med Res Review Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naïve and triple class resistant patients. It also has an excellent tolerability profile and lacks significant drug-drug interactions making it an important drug in the treatment of a number of special patient populations. In this review its use in patients undergoing solid organ and bone marrow transplantation and patients receiving cancer chemotherapy, will be discussed. In addition other indications including patients with metabolic complications of existing antiretroviral drugs as well as patients with side effects on current HAART regimens. Other groups of patients where raltegravir may play an important role are patients with renal disease and tuberculosis. Finally, although not licensed for use in pregnancy, raltegravir may need to be considered in some pregnant women with antiretroviral resistance or tolerability issues with current HAART regimens. BioMed Central 2009-11-24 /pmc/articles/PMC3516827/ /pubmed/19959416 http://dx.doi.org/10.1186/2047-783X-14-S3-43 Text en Copyright ©2009 I. Holzapfel Publishers
spellingShingle Review
Johnson, Margaret
Raltegravir use in special populations
title Raltegravir use in special populations
title_full Raltegravir use in special populations
title_fullStr Raltegravir use in special populations
title_full_unstemmed Raltegravir use in special populations
title_short Raltegravir use in special populations
title_sort raltegravir use in special populations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516827/
https://www.ncbi.nlm.nih.gov/pubmed/19959416
http://dx.doi.org/10.1186/2047-783X-14-S3-43
work_keys_str_mv AT johnsonmargaret raltegraviruseinspecialpopulations